Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?

被引：0
|
作者：
Helmut Oettle
Andreas Hilbig
机构：
[1] Berlin,H Oettle is an Associate Professor and A Hilbig is a Clinical Research Fellow in the Department of Medical Oncology and Hematology at the Charité School of Medicine
[2] Germany.,undefined
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：686 / 687
页数：1
相关论文
共 50 条
  • [41] INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ERLOTINIB/GEMCITABINE THERAPY IN PATIENTS WITH PANCREATIC CANCER
    Tanaka, Shigeru
    Shimokata, Tomoya
    Tsukuura, Hiroaki
    Maeda, Osamu
    Mitsuma, Ayako
    Ohno, Eizaburo
    Kawashima, Hiroki
    Hirooka, Yoshiki
    Goto, Hidemi
    Ando, Yuichi
    ANNALS OF ONCOLOGY, 2014, 25
  • [42] Strategies to improve the outcome in locally advanced pancreatic cancer
    Spath, C.
    Nitsche, U.
    Muller, T.
    Michalski, C.
    Erkan, M.
    Kong, B.
    Kleeff, J.
    MINERVA CHIRURGICA, 2015, 70 (02) : 97 - 106
  • [43] Erlotinib in the treatment of advanced pancreatic cancer
    Kelley, Robin K.
    Ko, Andrew H.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 83 - 95
  • [44] EFFICACY AND FACTORS AFFECTING OUTCOME OF GEMCITABINE CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER
    Huang, Pin- I.
    Chao, Yee
    Li, Chung-Pin
    Lee, Rheun-Chuan
    Chi, Kwan-Hwa
    Shiau, Cheng-Ying
    Wang, Ling-Wei
    Yen, Sang-Hue
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (01): : 159 - 165
  • [45] Does erlotinib improve symptoms in patients with lung cancer?: Commentary
    Jackman, David M.
    Jaenne, Pasi A.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (03): : 146 - 147
  • [46] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
    Moore, Malcolm J.
    Goldstein, David
    Hamm, John
    Figer, Arie
    Hecht, Joel R.
    Gallinger, Steven
    Au, Heather J.
    Murawa, Pawel
    Walde, David
    Wolff, Robert A.
    Campos, Daniel
    Lim, Robert
    Ding, Keyue
    Clark, Gary
    Voskoglou-Nomikos, Theodora
    Ptasynski, Mieke
    Parulekar, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966
  • [47] Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
    Han, Boram
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Kim, Jung Hoon
    Kim, Ho Young
    Song, Hunho
    Park, Choong Kee
    Moon, Sung Hoon
    Kim, Jong Hyeok
    Jeon, Jang Yong
    Lee, Jung Woo
    Zang, Dae Young
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] GEMCITABINE (G) FIXED RATE DOSE INFUSION (FDR) PLUS ERLOTINIB (E) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC)
    Munoz, A.
    Azkona, E.
    Iza, E.
    Martinez, M.
    Lopez-Vivanco, G.
    Fernandez, R.
    Ruiz De Lobera, A.
    Rubio, I.
    Casas, R.
    Mane, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 235 - 235
  • [49] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
    Vaccaro, Vanja
    Bria, Emilio
    Sperduti, Isabella
    Gelibter, Alain
    Moscetti, Luca
    Mansueto, Giovanni
    Ruggeri, Enzo Maria
    Gamucci, Teresa
    Cognetti, Francesco
    Milella, Michele
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (28) : 4511 - 4519
  • [50] Biweekly Gemcitabine (GEM) in Combination with Erlotinib (ERL): An Active and Convenient Regimen for Advanced Pancreatic Cancer
    Ardavanis, Alexandros
    Kountourakis, Panteleimon
    Karagiannis, Athanassios
    Doufexis, Dimitrios
    Tzovaras, Alexandros A.
    Rigatos, Gerasimos
    ANTICANCER RESEARCH, 2009, 29 (12) : 5211 - 5217
12345